Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy.
de Jager VD, Plomp P, Paats MS, van Helvert S, Elst AT, van den Berg A, Dubbink HJ, van Geffen WH, Zhang L, Hendriks LEL, Hiltermann TJN, Hiddinga BI, Hijmering-Kappelle LBM, Jalving M, Kluiver J, Koopman B, van Kruchten M, van der Logt EMJ, Piet B, van Putten J, Reitsma BH, Rutgers SR, de Vries M, Stigt JA, Groves MR, Timens W, Willems SM, van Kempen LC, Schuuring E, van der Wekken AJ. de Jager VD, et al. Among authors: hijmering kappelle lbm. ESMO Open. 2024 Nov;9(11):103966. doi: 10.1016/j.esmoop.2024.103966. Epub 2024 Nov 4. ESMO Open. 2024. PMID: 39500140 Free PMC article.
Baseline Blood CD8+ T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer.
Kievit H, Muntinghe-Wagenaar MB, Abdulahad WH, Rutgers A, Hijmering-Kappelle LBM, Hiddinga BI, Ubbels JF, Wijsman R, van der Leij MJ, Bijzet J, Groen HJM, Kerstjens HAM, van der Wekken AJ, Kroesen BJ, Hiltermann TJN. Kievit H, et al. Among authors: hijmering kappelle lbm. Cancers (Basel). 2024 Jul 19;16(14):2592. doi: 10.3390/cancers16142592. Cancers (Basel). 2024. PMID: 39061230 Free PMC article.
Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial.
Kievit H, Muntinghe-Wagenaar MB, Hijmering-Kappelle LBM, Hiddinga BI, Ubbels JF, Wijsman R, Slingers G, de Vries R, Groen HJM, Kerstjens HAM, van der Wekken AJ, Hiltermann TJN. Kievit H, et al. Among authors: hijmering kappelle lbm. Lung Cancer. 2023 Apr;178:96-102. doi: 10.1016/j.lungcan.2023.02.004. Epub 2023 Feb 7. Lung Cancer. 2023. PMID: 36806899 Free article. Clinical Trial.
The additional diagnostic value of virtual bronchoscopy navigation in patients with pulmonary nodules - The NAVIGATOR study.
Hiddinga BI, Slebos DJ, David Koster T, Hijmering-Kappelle LBM, Hiltermann TJN, Kievit H, van der Wekken AJ, de Jonge G, Vliegenthart R, Van De Wauwer C, Timens W, Bensch F. Hiddinga BI, et al. Among authors: hijmering kappelle lbm. Lung Cancer. 2023 Mar;177:37-43. doi: 10.1016/j.lungcan.2023.01.012. Epub 2023 Jan 24. Lung Cancer. 2023. PMID: 36708592 Free article.
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial.
Zwierenga F, van Veggel B, Hendriks LEL, Hiltermann TJN, Hiddinga BI, Hijmering Kappelle LBM, Ter Elst A, Hashemi SMS, Dingemans AC, van der Leest C, de Langen AJ, van den Heuvel MM, van der Wekken AJ. Zwierenga F, et al. Among authors: hijmering kappelle lbm. Lung Cancer. 2022 Aug;170:133-140. doi: 10.1016/j.lungcan.2022.06.012. Epub 2022 Jun 23. Lung Cancer. 2022. PMID: 35777160 Free article. Clinical Trial.
89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer.
Kok IC, Hooiveld JS, van de Donk PP, Giesen D, van der Veen EL, Lub-de Hooge MN, Brouwers AH, Hiltermann TJN, van der Wekken AJ, Hijmering-Kappelle LBM, Timens W, Elias SG, Hospers GAP, Groen HJM, Uyterlinde W, van der Hiel B, Haanen JB, de Groot DJA, Jalving M, de Vries EGE. Kok IC, et al. Among authors: hijmering kappelle lbm. Ann Oncol. 2022 Jan;33(1):80-88. doi: 10.1016/j.annonc.2021.10.213. Epub 2021 Nov 1. Ann Oncol. 2022. PMID: 34736925 Free article.
Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature.
Koopman B, Groen HJM, Schuuring E, Hiltermann TJN, Timens W, den Dunnen WFA, van den Berg A, Ter Elst A, van Kruchten M, Kluiver JL, Hiddinga BI, Hijmering-Kappelle LBM, Groves MR, Vilacha JF, van Kempen LC, van der Wekken AJ. Koopman B, et al. Among authors: hijmering kappelle lbm. Clin Lung Cancer. 2022 Mar;23(2):e104-e115. doi: 10.1016/j.cllc.2021.06.011. Epub 2021 Jul 3. Clin Lung Cancer. 2022. PMID: 34325996 Free article. Review.
Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles.
Koopman B, van der Wekken AJ, Ter Elst A, Hiltermann TJN, Vilacha JF, Groves MR, van den Berg A, Hiddinga BI, Hijmering-Kappelle LBM, Stigt JA, Timens W, Groen HJM, Schuuring E, van Kempen LC. Koopman B, et al. Among authors: hijmering kappelle lbm. JCO Precis Oncol. 2020 Nov;4:393-410. doi: 10.1200/PO.20.00008. JCO Precis Oncol. 2020. PMID: 35050740